TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

Immuron Announces Clinical Trial Update

GlobeNewswire Inc. Logo GlobeNewswire Inc. By Steven Lydeamore
Immuron Announces Clinical Trial Update

Immuron Limited submitted an Investigational New Drug (IND) application to the FDA for IMM-529, targeting Clostridioides difficile infection. The company's Travelan® P2TD study results are delayed until November 2025 due to government shutdown, with potential implications for future dosing strategies.

Insights
PFE   positive

Listed as a key market player with strong potential in developing advanced anti-inflammatory treatments


IMRN   neutral

Company is progressing clinical trials and regulatory submissions, with some delays but continuing active development of pharmaceutical products